You have probably never heard his name. That is exactly how Osagie Imasogie operates.
While Nigeria celebrates the loud victories, the tech founders, the entertainers, the athletes, there is a man based in Philadelphia who has spent the last three decades quietly reshaping the American pharmaceutical industry, one company at a time.
He does not make headlines. He makes deals, and the deals he makes are worth billions. 
Osagie Imasogie is a business executive and solicitor with over 36 years of experience across law, finance, business management, healthcare, and the pharmaceutical industry. That description sounds standard until you look at what he has built.
How He Got Here
According to Penn Carey Law, Imasogie holds LLM degrees from the London School of Economics and the University of Pennsylvania Carey Law School, and is a member of the New York State Bar. His education alone spans two continents.
He began his legal career in Nigeria, did postgraduate work in London, came to Penn for his doctorate in law, and then built a career that moved through law, corporate finance, and eventually deep into pharmaceutical deal-making.
Before co-founding PIPV Capital, Imasogie conceptualised and established GlaxoSmithKline Ventures and was its founding Vice President, leading GSK Ventures in concluding 30 worldwide transactions within a three-year period. Thirty deals in three years. That is not a career. That is a machine.
Imasogie also served as a Vice President at GlaxoSmithKline Research and Development and was instrumental in the external value maximisation of various GlaxoSmithKline assets, compounds, technology platforms, databases, compound libraries, and patents.
The Empire He Built
Here is where it gets interesting. Imasogie founded Endo Pharmaceuticals in 1997, where he served as SVP of Business Development and General Counsel.
He also founded Ception Therapeutics, Trigenesis Therapeutics, iCeutica, Iroko Pharmaceuticals, and Churchill Pharmaceuticals, amongst others. He helped nurture Endo Pharmaceuticals into a $4 billion firm.
He is a co-founder of PIPV Capital, a private equity firm focused on the life sciences sector that has invested over $1 billion in the pharmaceutical industry.
Imasogie also serves on the boards of financial institutions including FS-KKR Capital Corp and Haverford Trust, which, according to FunTimes Magazine, together manage over $28 billion in assets. He is an adviser to Brown Advisory, a firm overseeing over $140 billion.
These are not small numbers. These are the numbers of someone who has been operating at the highest level of American finance and medicine for decades, quietly, consistently, and without much fanfare.
SEE ALSO: Davido’s 4th Baby Mama, Larissa London Lashes Out At Women Doing Juju Against Her Son
Beyond Business
Imasogie is a Trustee of the University of Pennsylvania and Chairman of the Board of the University of Pennsylvania Carey Law School, where he is also an Adjunct Professor teaching a seminar on Intellectual Property and National Economic Value Creation.
He and his wife Losenge established the Imasogie Gateway, which serves as the main entrance into Golkin Hall at Penn Carey Law, and created the Imasogie Professorship in Law and Technology.
In 2023, US President Joe Biden appointed him to the President’s Advisory Council on African Diaspora Engagement in the United States.
The Nigerian man who built a pharmaceutical empire never needed the noise. The results were always going to speak for themselves.
About The Author
Keep Up to Date with the Most Important News
